• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Noel G. Boyle Discusses Benefits of Dabigatran Versus Warfarin for Treatment of Atrial Fibrillation

Article

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are at risk for stroke.

In addition, Dr. Boyle discusses the benefits of dabigatran (Brand name: Pradaxa) versus warfarin for the treatment of patients with atrial fibrillation. According to Dr. Boyle, advantages of dabigatran include no patient monitoring, fixed dosing, and less drug interactions. Disadvantages of dabigatran include twice daily dosing and no easy method for monitoring, according to Dr. Boyle.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.